San Antonio, TXNCT04665206Now EnrollingIRB Ready

Metastatic Cancer Clinical Trial in San Antonio, TX

Access cutting-edge metastatic cancer treatment through this phase 1/2 clinical trial at a research site in San Antonio. Study-provided care at no cost to qualified participants.

Sponsored by Vivace Therapeutics, Inc

Quick Self-Assessment

See if you qualify for this San Antonio location

Preparing your pre-screening questions…

Expert Care in San Antonio

Access metastatic cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic cancer treatment provided free

Apply for This San Antonio Location

Check if you qualify for this metastatic cancer clinical trial in San Antonio, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Antonio

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Antonio site if eligible
  4. 4Begin participation

About This Metastatic Cancer Study in San Antonio

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Sponsor: Vivace Therapeutics, Inc

Who Can Participate

Inclusion Criteria

Part 3 Combination Cohort A: Patients with pathologically diagnosed, metastatic or unresectable malignant mesothelioma (including both pleural and non-pleural) who have not received systemic therapy.
Part 3 Combination Cohort B: Patients with pathologically diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib.
Part 3 Combination Cohort C: Patients with pathologically diagnosed metastatic or unresectable malignant pleural mesothelioma who have not received systemic chemotherapy.
Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma.
Adequate organ functions, including the liver, kidneys, and hematopoietic system.

Exclusion Criteria

Active brain metastases or primary CNS (central nervous system) tumors.
History of leptomeningeal metastases
Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Known HIV positive or active Hepatitis B or Hepatitis C
Clinically significant cardiovascular disease and prior exposure to cardiotoxic agents.
Corrected QT (QTcF) interval \> 470 msec (using Fridericia's correction formula).
Additional active malignancy that may confound the assessment of the study endpoints
Women who are pregnant or breastfeeding
Prior treatment with TEAD inhibitor.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Antonio?

Yes, this clinical trial (NCT04665206) has an active research site in San Antonio, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Cancer Treatment Options in San Antonio, TX

If you're searching for metastatic cancer treatment options in San Antonio, TX, this clinical trial (NCT04665206) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Antonio research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced metastatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic cancer clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in San Antonio, TX

See all advanced solid tumors clinical trials recruiting in San Antonio — not just this study.

Browse Advanced Solid Tumors Trials in San Antonio →

Browse More Trials by Condition

Advanced Solid Tumors TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in San Antonio?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Antonio, TX